P.O. Box 50030 London, ON N6A 6H8 info@rett.ca (519) 474-6877

Tag: Acadia

DAYBUE – Breaking News

Approves Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome.  DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare neurodevelopmental disorder. We recognize the… Read More

2025 Calendars

Order your Copy Today! We are beyond excited to share the 2025 O.R.S.A. Calendar, where art, resilience, and community come together form coast to coast in the most beautiful way! Created by individuals with Rett syndrome and their amazing… Read More

Priority Review by Health Canada

Just announced at the 2024 Ascend Rett National Conference, Health Canada has accepted regulatory applications from Acadia Pharmaceuticals for DayBue (Trofinetide), but has also been accepted for a priority review by Health Canada. We were honored to be… Read More